Obicetrapib for dyslipidemia with or without cardiovascular risk: A <scp>GRADE</scp> ‐assessed meta‐analysis of randomized trials with trial sequential evidence
Obicetrapib provides substantial improvements in lipid parameters with a favourable short-term adverse events rate. These results support its role as a potential adjunctive lipid-lowering agent irrespective of ASCVD risk. Longer-term trials are warranted to confirm its durability, cardiovascular outcomes, and safety.
Authors
- Abdalhakim R. M. Shubietah (ORCID: https://orcid.org/0000-0002-8300-0262)
- Ahmed Farid Gadelmawla (ORCID: https://orcid.org/0000-0002-5802-2291)
- Abdalrahman Assaassa
- Mohamed Emara (ORCID: https://orcid.org/0000-0003-1331-6365)
- Ramez M. Odat (ORCID: https://orcid.org/0009-0008-3423-4055)
- Ameer Awashra (ORCID: https://orcid.org/0009-0002-5122-8200)
- Ahmed Emara (ORCID: https://orcid.org/0009-0001-2718-8627)
- Mohamed S. Elgendy (ORCID: https://orcid.org/0000-0003-3080-2875)
- Ahmed Diaa
- Mohamed Rifai (ORCID: https://orcid.org/0009-0007-9457-9832)
Institutions
- Jordan University of Science and Technology (JO)
- An-Najah National University (PS)
- Al-Azhar University (EG)
- Tanta University (EG)
- Thomas Jefferson University Hospital (US)
- Advocate Illinois Masonic Medical Center (US)
- Menoufia University (EG)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1111/dom.70316
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.01